234450-04-5

Upstream product

• 693222-16-1 [5-(5-benzyloxycarbonylamino-1-chloroacetyl-pentylcarbamoyl)-5-tert-butoxycarbonylamino-pentyl]-carbamic acid benzyl ester 
• 172833-14-6 ((S)-5-tert-Butoxycarbonylamino-7-diazo-6-oxo-heptyl)-carbamic acid benzyl ester 
• 2389-45-9 6-(((benzyloxy)carbonyl)amino)-2-((tert butoxycarbonyl)amino)-hexanoic acid 
• 693222-12-7 (5-tert-butoxycarbonylamino-7-chloro-6-oxo-heptyl)-carbamic acid benzyl ester 
• 788822-08-2 (5-amino-7-chloro-6-oxo-heptyl)-carbamic acid benzyl ester 

Downstream Products

• 872043-69-1 C₆₅H₈₄N₈O₁₁ 
• 234450-13-6 [1-[4-(5-{4-[2-tert-butoxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-butyl}-3-methyl-6-oxo-1,6-dihydro-pyrazin-2-yl)-butylcarbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Potent Dmt-Tic pharmacophoric δ- and μ-opioid receptor antagonists

A series of dimeric Dmt-Tic (2′,6′-dimethyl-L-tyrosyl-1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid) analogues (8-14, 18-22) were covalently linked through diaminoalkane and symmetric or asymmetric 3,6-diaminoalkyl-2(1H)-pyrazinone moieties. All the c

Immediate deamination from the aminomethyl group attached to 1,2-dihydropyrazin-2-one derivative during catalytic hydrogenation

The catalytic hydrogenation of 3,6-bis(benzyloxycarbonylaminomethyl)-5-methyl-1,2-dihydropyrazin-2-one to remove benzyloxycarbonyl (Z) groups resulted in a side reaction. Purification by reverse-phase HPLC and analysis by proton nuclear magnetic resonance